 |
| BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence. |
|---|
|
   |
| MJTV Adds Medical Cannabis Guru as Chief Medical Advisor |
|
 Hot Stock to Watch |
Company: Michael James Enterprises Inc. (OTCQB: MJTV)
|
Last:
Price: 0.043
Change (%): + 0.005 (13.16)
Volume: 97,722 |
 |
MJTV Engages Dr. Gregory Smith As Chief Medical Advisor
WHIPPANY, NJ-(Marketwired - Jan 25, 2017) - Michael James Enterprises, Inc. (OTCQB: MJTV) is extremely pleased to bring on Gregory Smith, M.D. as Chief Medical Advisor to consult with MJTV on the Voluptas Project as well the different Neuroceuticals the Company has under development.
Dr. Smith earned his medical degree from Rush Medical School in Chicago as well as his Master of Public Health from Harvard University. He completed residency training in Preventive Medicine at Walter Reed Army Medical Center. Since leaving the US Army with the rank of Major, Doctor Smith has been in primary Practice care in California, Georgia and Florida for the past 25 plus years.
Doctor Smith trained on the use of cannabinoid pharmaceuticals in California in 2000, and has consulted with several biosynthetic cannabinoid manufacturers over past four years. Dr. Smith wrote “Medical Cannabis: Basic Science and Clinical Applications,” in 2016 published by Aylesbury Press. This has become the standard textbook for medical professionals using cannabinoid medication in their practice. He has written many magazine articles and has over a dozen peer reviewed medical publications.
MJTV CEO, James M. Farinella stated, “Dr. Gregory Smith is such a valuable addition to the MJTV team. His extensive knowledge on the various delivery methods for over-the-counter supplements has added great value to our VOLUPTAS Project and his extensive training and work in the cannabinoid field as a doctor should yield tremendous opportunities for MJTV moving forward.”
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
